- Home
- ABUS vs MATV Comparison
ABUS vs MATV Comparison
Compare ABUS & MATV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- MATV
- Stock Information
- Founded
- ABUS 2005
- MATV 1995
- Country
- ABUS United States
- MATV United States
- Employees
- ABUS N/A
- MATV N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- MATV Paper
- Sector
- ABUS Health Care
- MATV Basic Materials
- Exchange
- ABUS Nasdaq
- MATV Nasdaq
- Market Cap
- ABUS 711.2M
- MATV 671.4M
- IPO Year
- ABUS N/A
- MATV 1995
- Fundamental
- Price
- ABUS $4.46
- MATV $11.55
- Analyst Decision
- ABUS Strong Buy
- MATV Strong Buy
- Analyst Count
- ABUS 2
- MATV 1
- Target Price
- ABUS $5.00
- MATV $10.00
- AVG Volume (30 Days)
- ABUS 930.7K
- MATV 381.9K
- Earning Date
- ABUS 11-10-2025
- MATV 11-05-2025
- Dividend Yield
- ABUS N/A
- MATV 3.46%
- EPS Growth
- ABUS N/A
- MATV N/A
- EPS
- ABUS N/A
- MATV N/A
- Revenue
- ABUS $15,416,000.00
- MATV $1,967,300,000.00
- Revenue This Year
- ABUS $138.02
- MATV $3.68
- Revenue Next Year
- ABUS N/A
- MATV $2.82
- P/E Ratio
- ABUS N/A
- MATV N/A
- Revenue Growth
- ABUS 53.23
- MATV N/A
- 52 Week Low
- ABUS $2.71
- MATV $4.34
- 52 Week High
- ABUS $5.10
- MATV $17.47
- Technical
- Relative Strength Index (RSI)
- ABUS 54.42
- MATV 57.21
- Support Level
- ABUS $4.26
- MATV $10.41
- Resistance Level
- ABUS $4.61
- MATV $11.29
- Average True Range (ATR)
- ABUS 0.20
- MATV 0.48
- MACD
- ABUS -0.01
- MATV 0.08
- Stochastic Oscillator
- ABUS 65.45
- MATV 88.21
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About MATV Mativ Holdings Inc.
Mativ Holdings Inc is a diversified producer of premium specialty papers and resin-based products. It manufactures and sells paper and reconstituted tobacco products to the tobacco industry as well as specialized paper products. The company operates in two segments namely Advanced Materials and Structures, which manufactures resin-based products used in specialty applications in the filtration, infrastructure and construction, transportation, industrial, and medical end-markets, and Engineered Papers, which produces cigarette papers and reconstituted tobacco products for cigarette and cigar manufacturers, as well as various other non-tobacco paper products.